Search
Huiyu Pharmaceutical Announces First Patient Dosed in Phase I Clinical Trial of HY05350 Injection
2025-08-04 /
Read about 0 minute
Author：小编
Huiyu Haiyue, a wholly-owned subsidiary of our company, has successfully dosed the first patient in a Phase I clinical trial of its independently developed Class 1 biological innovative drug, HY05350 Injection, for the treatment of advanced solid tumors. As of June 30, 2025, approximately RMB 76.4282 million has been invested in research and development for this groundbreaking project.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
